Pulse Biosciences, Inc. announced favorable findings from the 60-day post-procedure evaluations for four initial patients treated in the Company?s CellFX nsPFA 360° Cardiac Catheter First-In-Human Feasibility Study. Using the Company?s CellFX nsPFA 360° Cardiac Catheter, 14 patients with atrial fibrillation (AF) have been successfully treated at Na Homolce Hospital in Prague, Czech Republic. Patients treated with the Company?s CellFX nsPFA 360° Cardiac Catheter system are being evaluated at regular intervals to further document the safety and effectiveness of the treatments, and the Company expects to enroll up to a total of 30 patients in the current feasibility study.

The Company has remapped the first four of the initial 14 patients treated. The observations to date have been positive, but the broad set of risks associated with cardiac surgery remain.